CNS Clinical Trials:

Suicidality and Data Collection: Workshop Summary

Status: Available Now

Size: 88 pages, 6x9

Publication Year:2010

Print	List Price


PAPERBACK ISBN-10: 0-309-14883-9 ISBN-13: 978-0-309-14883-2	$21.00	Add to Cart

PDF			About PDF

Authors:
Sarah Hanson, Miriam Davis, and Bruce Altevogt, Rapporteurs; Forum on Neuroscience and Nervous System Disorders
Authoring Organizations

Description:

Paste into your Web page:

<!-- Start NAP Book Display -->
<object classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=8,0,0,0" width="175" height="250" id="napbookwrapper" align="middle">
<param name="allowScriptAccess" value="always" />
<param name="movie" value="http://www.nap.edu/napbookwrapper.swf" />
<param name="quality" value="high" />
<param name="wmode" value="transparent" />
<param name="flashvars" value="wid=501710924820130522191025&record_id=12829" />
<embed src="http://www.nap.edu/napbookwrapper.swf" quality="high" flashvars="wid=501710924820130522191025&record_id=12829" wmode="transparent" bgcolor="#ffffff" width="175" height="250" name="napbookwrapper" align="middle" allowScriptAccess="always" allowFullScreen="false" type="application/x-shockwave-flash" pluginspage="http://www.macromedia.com/go/getflashplayer"></embed>
</object>

Preview

Free Resources

Full Text
Jump to this book's table of contents to begin reading online for free.

Related Items:
Related Titles

PDF Summary
Download the summary in PDF.

Reprint Permission
Request permission to license or reprint the book's content through Copyright Clearance Center's Rightslink.

Request Permission to Distribute a PDF

Request Translation Rights

Questions About Rights and Permissions?

Table of Contents
Select a link below to start reading online free!
Front Matter	i-xii
Introduction	1-6	(skim)
1 Perspectives from the FDA, Academia, and Patients	7-16	(skim)
2 Data Collection and Optimization	17-24	(skim)
3 Data Analysis	25-34	(skim)
4 Partnerships, Opportunities, Collaboration	35-42	(skim)
Appendix A: References	43-50	(skim)
Appendix B: Workshop Agenda	51-60	(skim)
Appendix C: Workshop Attendees	61-64	(skim)
Appendix D: Biographical Sketches of Invited Speakers	65-76	(skim)

Description

The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.

CNS Clinical Trials:

Suicidality and Data Collection: Workshop Summary

Citation Manager

Description

Authoring Organizations

Search This Book

SIGN UP FOR...